SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced the pricing of an underwritten

#SABS #SABSW SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants SAB Biotherapeutics (Nasdaq: SABS) commenced an underwritten public offering of common stock and, for certain investors, pre-funded warrants on March 17, 2026. The company also plans to grant underwriters a 30-day option to buy up to an additional 15% of the offered securities.Proceeds, together with existing cash and marketable securities, are intended primarily to fund continued development of SAB-142 (clinical trials, manufacturing, regulatory), and for working capital and general corporate purposes. The offering is made on a Form S-3 shelf registration declared effective January 7, 2026, and is subject to market conditions.

#SABS #SABSW SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes SAB BIO (Nasdaq: SABS) reported additional Phase 1 data for SAB-142 in adults with established type 1 diabetes showing early signals of C‑peptide preservation at Day 120 in treated participants versus placebo. The small cohort (n=6; 4 treated, 2 placebo) showed biomarker evidence of T‑cell exhaustion. SAB‑142 has advanced to the registrational Phase 2b SAFEGUARD trial with topline data expected 2H 2027.

#SABS #SABSW SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy volunteer, redosing, and T1D cohorts supporting

#SABS #SABSW SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

www.stocktitan.net/news/SABS/sab-bio-report...

Trade Alerts, Wednesday January 14, 2026 – Crystal Equity Research

Small-cap stocks with improving money flow, Wed Jan 14th - #XOMA #WBTN #TBPH #SABS #ACHV #BOOM #CHCO #FOSL #GNPX #IMCC #KXIN #MAZE #NEWT #ORMP #UA #RYAM #PKST #NGVC #LXFR #GCO #FCRS #DCO #CC #ADNT - More: crystalequityresearch.com/trade-alerts... - #smallcap

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D SAB BIO (Nasdaq: SABS) announced positive confirmatory Phase 1 results for SAB-142, an hATG candidate for stage 3 type 1 diabetes (T1D). In 68 treated participants (healthy volunteers and T1D patients), SAB-142 showed 0% serum sickness (0/68), 0% anti-drug antibody events (0/68), no drug-related serious adverse events, and transient lymphopenia that resolved to baseline within 1–3 days in 100% of subjects (68/68). Most adverse events were mild and infusion-related. A registrational Phase 2b SAFEGUARD trial is underway and recruiting globally, with the company on track to dose the first patient by year-end.

#SABS #SABSW SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights SAB BIO (Nasdaq: SABS) initiated its registrational Phase 2b SAFEGUARD trial of lead candidate SAB-142 in new-onset Stage 3 T1D, activated multiple sites in the US, Australia and New Zealand, and is on-track to dose the first patient by year-end 2025. The company reported a strong cash position of $161.5 million at Sept 30, 2025 (vs. $20.8 million at Dec 31, 2024) and said its runway extends through 2028. Phase 1 data presented at EASD and ISPAD showed a favorable safety profile, no serum sickness or anti-drug antibodies at the target dose, and sustained immunomodulation. Financials: Q3 R&D $9.0M, other income $58.1M, and Q3 net income $45.4M. Company expects SAFEGUARD data in 2H 2027 and to present additional Phase 1 redosing data by year-end 2025.

#SABS #SABSW SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

www.stocktitan.net/news/SABS/sab-bio-report...

In The Rock 11/4/1981: Black Sabbath release ‘Mob Rules’, their second LP with Ronnie James Dio on vocals, and first with drummer Vinnie Appice. Well received by fans, the record was slagged by some critics. #BlackSabbath #Dio #Sabs #RockHonorRoll

An illustration in green and beige tones depicts a fox hunting scene with riders in red jackets and black hats on horseback jumping over a wooden fence. A brown horse with a rider in front leads, followed by a gray horse with another rider. Additional riders and horses are visible in the background amid a rural landscape with trees, grass, and hills.

Perhaps the connection between #SpyCops and #RobertSmith-#Surtees' character #Jorrocks is #Fox-#Hunting.

See Bob #Lambert and his cohorts' infiltration of #Brixton and #Croydon #Sabs (and #Saab).

See Previous posts regarding John #Mills' statue of Jorrocks in Croydon and ...

Symptom Of The Universe 🤘🏻🤘🏻🤘🏻🤘🏻 #np #Sabs #BlackSabbath

Breakthrough in Type 1 Diabetes: SAB BIO's SAB-142 Shows Sustained Effects Without Lymphodepletion in Phase 1 SAB BIO presents Phase 1 data for SAB-142 in T1D showing sustained immunomodulation without lymphodepletion. Study included 68 subjects, with effects lasting 120 days. Phase 2b SAFEGUARD study now initiated.

#SABS #SABSW SAB BIO Highlights Data in Multiple Presentations at EASD

www.stocktitan.net/news/SABS/sab-bio-highli...

Breakthrough Type 1 Diabetes Treatment: SAB BIO to Showcase Novel Immunotherapy SAB-142 in 5 EASD Sessions SAB Biotherapeutics will deliver 4 oral presentations and symposium on SAB-142, a human anti-thymocyte immunoglobulin for type 1 diabetes, at EASD 2025 in Vienna, September 15-19.

#SABS #SABSW SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

www.stocktitan.net/news/SABS/sab-bio-to-del...

#SAMVs
#SAMSs
#SAMV's
#SAMS's

#SAMMHs
#SAMHs
#SAMMH's
#SAMH's

#SAMs
#SABs
#SAM's
#SAB's

#SAMBs
#SAMABs
#SAMVs
#SAMSs

#SAMB's
#SAMAB's
#SAMV's
#SAMS's

SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates SAB BIO (Nasdaq: SABS) has announced significant developments in Q2 2025, highlighted by a $175 million oversubscribed private placement that included strategic investor Sanofi. The financing extends the company's operational runway until mid-2028 and will fully fund their pivotal Phase 2b SAFEGUARD study for SAB-142, their lead candidate for delaying type 1 diabetes progression.The company achieved FDA alignment on the SAFEGUARD study design, scheduled to begin in Q3 2025. The private placement included issuing 1 million shares of Series B preferred stock at $1.75 per share conversion price, plus warrants for potential additional proceeds of $284 million.Financial results showed cash position of $5.7 million as of June 30, 2025, with Q2 R&D expenses at $7.0 million and a net loss of $10.1 million.

#SABS #SABSW SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

www.stocktitan.net/news/SABS/sab-bio-report...

In The Rock 8/7/1983: Black Sabbath release their eleventh studio album, ‘Born Again’, their only record with Deep Purple singer Ian Gillan on vocals. #BlackSabbath #Sabs #IanGillan

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Mon Jul 21st - #OPAD #SLDP #ABCL #UPXI #RXRX #GCTK #SABS #DNN #RAYA #LMFA #EOSE #SBET #HSDT #OPEN #BMNR #SRPT #AZ #ARQQ #RZLV #AAOI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SAB BIO Announces Oversubscribed $175 Million Private Placement SAB BIO (Nasdaq: SABS) has secured a significant $175 million private placement with participation from strategic investor Sanofi and several prominent institutional investors. The oversubscribed financing includes the issuance of 1,000,000 shares of Series B nonvoting convertible preferred stock at a conversion price of $1.75 per share.The company will also issue warrants that could provide up to an additional $284 million in gross proceeds if exercised in full. The proceeds will fund the pivotal Phase 2b SAFEGUARD study of SAB-142 for delaying progression of autoimmune Type 1 Diabetes (T1D) in newly diagnosed patients, extending the company's cash runway into mid-2028.

#SABS #SABSW SAB BIO Announces Oversubscribed $175 Million Private Placement

www.stocktitan.net/news/SABS/sab-bio-announ...

In The Rock 7/13/1968: Earth, eventually to be known as Black Sabbath, perform live for the first time in Birmingham,UK. #BlackSabbath #Sabs #RockHonorRoll

Road To Wrath, by Big Scary Indian 3 track album

Today’s fave new (to me) band: #BigScaryIndian. Imagine “THRaK”-era #Crimson, #Battles, #Ponytail, early #Sabs, “Nothingface”-era #Voivod, #Thundercat, and #BrandX all smudged together, remixed by #SOPHIE.

The shit!

@risottodrake.bsky.social - you might dig!

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Thu May 22nd - #BON #ABVX #XAGE #VALN #TIL #SABS #QMCO #NVTS #IOBT #HOOK #CREX #FGL #DOMO #CNCK #BDRX #AMSC #VCSA #SMWB #AAP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates SAB BIO (NASDAQ: SABS) has reported its Q1 2025 financial results and company updates. The clinical-stage biopharmaceutical company completed patient dosing in the last cohort of the Phase 1 clinical study of SAB-142, their novel immunotherapy for delaying type 1 diabetes progression. The company reported cash and equivalents of $12.9 million, down from $20.8 million in December 2024.Financial highlights include R&D expenses of $7.7 million (down from $8.1 million YoY), reduced G&A expenses of $3.1 million (down from $4.2 million YoY), and other income of $5.6 million. The company reported a net loss of $5.2 million. SAB BIO also achieved a significant milestone by obtaining a Qualified Person declaration for their in-house CMC manufacturing process, enabling them to meet European manufacturing standards for upcoming EU clinical trials.

#SABS #SABSW SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB Bio's Diabetes Breakthrough: Phase 1 Success Drives Path to Phase 2b Trials Type 1 Diabetes therapy SAB-142 achieves safety and efficacy goals in Phase 1, advancing to Phase 2b amid improved annual losses. See full clinical and financial details.

#SABS #SABSW SAB BIO Reports Full Year 2024 Operating and Financial Results

www.stocktitan.net/news/SABS/sab-bio-report...

SABS Unveils Noir-Pop Anthem “justlikethat” Rising noir-pop artist SABS returns with her latest single, “justlikethat”, proving she has no plans of slowing down following her previous release, “demons”. With reverb-soaked vocals, hypnotic melodies, and a dark yet alluring production, SABS crafts an alternative sound that blends lo-fi, alt-rock, and ethereal pop elements. The track opens with a dreamy arpeggiator, pulling listeners into its…

#SABS Unveils Noir-Pop Anthem “justlikethat”

Are you ready for the July 2026 #SABS changes? Be prepared! Join us Feb 12 for "Herding CATS" & get expert medical & legal insights. Register now!
🔗 https://buff.ly/3WPdv98

Revolutionary Type 1 Diabetes Drug Aces Safety Tests, Outpatient Treatment Now Possible SAB BIO's SAB-142 achieves key trial milestones for type 1 diabetes treatment, demonstrating exceptional safety and sustained immunomodulation. Phase 2b trials planned for 2025.

#SABS #SABSW SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

www.stocktitan.net/news/SABS/sab-bio-announ...

SAB BIO to Present Phase 1 Type 1 Diabetes Treatment Data in Upcoming R&D Webinar SAB BIO announces R&D webinar featuring Phase 1 trial results for SAB-142, a novel immunotherapy treatment for type 1 diabetes, with expert Dr. Michael Haller on January 28.

#SABS #SABSW SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

www.stocktitan.net/news/SABS/sab-bio-announ...

Indie Pop from SABS

SABS shares recent single "turnstiles"

#sabs #turnstiles #new #music #newmusic #newmusicnow #indie #pop #indiepop #alternativepop #artist #germantown #maryland #usa #plastic #plasticmag

a blue thank you card with pink hearts ALT: a blue thank you card with pink hearts

To all the #Sabs of hunting that takes place all year round but in particular Boxing Day in a particular culture...

They risk life limb and liberty as they organize the sabotaging of these hunts that,for the most part, are illegal though these psychopaths have found loopholes

Be a Saboteur!

Do people still want to be part of established hunts with hounds?

They are not charities, do no benefit.

End the National shame of the Boxing Day hunts by offering a better alternative with fun local horse only meets.

Leave the dogs at home.
#fox-hunting
#horses
#leave-the-dogs-at-home
#sabs